Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 13/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 13/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 13/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6470647 | 0.79 | CSNK2A2 (0.44) | CSNK2A2CSNK2BCSNK2A1NUDT1CDK2 | |
| SCHEMBL29956848 | 0.77 | ALPG (0.60) | CSNK2A2CSNK2BCSNK2A1NUDT1CDK2 | |
| SCHEMBL11360823 | 0.77 | ALPG (0.60) | CSNK2A2CSNK2BCSNK2A1NUDT1CDK2 | |
| SCHEMBL6471096 | 0.71 | ALPG (0.62) | CSNK2A2CSNK2BCSNK2A1TP53ATM | |
| SCHEMBL21623744 | 0.71 | CSNK2A2 (0.49) | CSNK2A2CSNK2BCSNK2A1CDK2ATM | |
| SCHEMBL16707578 | 0.71 | CSNK2A2 (0.48) | CSNK2A2CSNK2BCSNK2A1NUDT1TP53 | |
| SCHEMBL11399024 | 0.70 | NQO1 (0.41) | TP53ALPGMAPTTHRBPOLB | |
| SCHEMBL7253352 | 0.69 | TTR (0.67) | MAPT | |
| SCHEMBL29838129 | 0.69 | TTR (0.67) | MAPT | |
| Xanthone SCHEMBL10615991 | 0.68 | TTR (0.65) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | CSNK2A2 2448/4885CSNK2B 2625/4885CSNK2A1 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.